× Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our privacy policy


× Important note: This Web site presents preliminary results. We are working non-stop to complete the biocuration as soon as possible.

meta|Evidence - COVID-19

Live meta-analysis and evidence synthesis of potential therapies for COVID19

  Summary of results of all meta-analysis  
tutorial video
En     Fr

Our approach


adjuvant therapies

anticoagulant 2

Bivalirudin

colchicine 1

hydrogen-oxygen nebulizer

hyperbaric oxygen

nintedanib

pulmonary rehabilitation

thalidomide

vitamin C

anti-inflammatoty and immuno-therapy

anti-inflammatory therapies 1

IFX-1

naproxen, ibuprofen

non-steroidal anti-inflammatory drugs

sodium aescinate

Apilimod

corticosteroids 6

ciclesonide

dexamethasone 1

inhaled steroids

low-dose corticosteroids

imatinib

Immunostimulants drugs

anti-PD-1 antibody

CD24Fc

convalescent plasma treatment 7

immunoglobulin therapy

emapalumab

inactivated mycobacterium vaccine

Interleukin-2

rhG-CSF

vaccines

Immunosuppressants drugs

anakinra

eculizumab

interleukin-6 inhibitor

clazakizumab

sarilumab 1

sarilumab azithromycin hydroxychloroquine

sarilumab high dose (400mg) 1

sarilumab low dose (200mg) 1

siltuximab

tocilizumab 10

jakotinib

lenzilumab

ruxolitinib

tacrolimus

tetrandrine

leflunomide

pirfenidone

Polyinosinic-Polycytidylic Acid

sargramostim

thymosin

antiviral and associated therapy

ASC09/ritonavir

azithromycin 1

azvudine

baloxavir marboxil

bromhexine

carrimycin

chloroquine and derivatives 5

chloroquine 1

hydroxychloroquine 13

danoprevir / ritonavir

darunavir cobicistat

darunavir/cobicistat plus chloroquine

favipiravir 1

hydroxychloroquine plus macrolides 6

interferon

SNG001 inhaled interferon beta 1

ivermectin

leronlimab

lopinavir / ritonavir plus ribavirin

lopinavir/ritonavir 3

lopinavir/ritonavir plus interferon ß-1a

lopinavir/ritonavir, ribavirin and interferon beta-1b

meplazumab

oseltamivir plus chloroquin

remdesevir 2

Renin-angiotensin-system-acting agents 6

angiotensin receptor blockers (ARBs)

angiotensin-(1-7)

RAS blocker withdrawal

rhACE2

ritonavir

tranexamic acid

triazavirin

umifenovir (arbidol) 1

control

prone positioning

miscellaneous

acetylcysteine

alpha lipoic acid 1

aviptadil

bevacizumab

bismuth

BLD-2660 (calpain inhibitor)

camostat mesilate

continuous positive airway pressure (CPAP)

cytokine adsorption

diammonium glycyrrhizinate

dipyridamol

enoxaparin

levamisole

natural killer (NK) cells

nitric oxide (gas Inhalation or releasing solution)

ozonated autohemotherapy

pamrevlumab

PUL-042 inhalation solution

selinexor

stem cells

tradipitant

tranilast

Latest studies

COVACTA unpublished   NCT04320615 5 days ago

tocilizumab vs. placebo - COVID-19 severe or critically low risk of bias

    COVACTA trial did not meet its primary endpoint of improved clinical status in patients with COVID-19 associated pneumonia, or the key secondary endpoint of reduced patient mortality

  • inconclusive results for: clinical improvement

meta-analysis

Mitja , 2020   NCT04304053 8 days ago

hydroxychloroquine vs. control - COVID-19 prophylaxis some concern in risk of bias

  • inconclusive results for: death; PCR-confirmed, symptomatic Covid-19 disease

meta-analysis

Coalition Covid-19 Brazil I , 2020   NCT04322123 2 weeks ago

hydroxychloroquine plus macrolides vs. standard of care - COVID-19 mild to moderate some concern in risk of bias

  • inconclusive results for: 15 days clinical worsening (7 levels ordinal scale); in hospital deaths

meta-analysis

Coalition Covid-19 Brazil I , 2020   NCT04322123 2 weeks ago

hydroxychloroquine vs. standard of care - COVID-19 mild to moderate some concern in risk of bias

  • inconclusive results for: 15 days clinical worsening (seven-point ordinal scale); death

meta-analysis

SNG001 inhaled interferon beta vs. placebo - COVID 19 hospitalized NA risk of bias

  • suggested 2.2-fold increase in recovery
  • suggested 79 % decrease in 16-day ventilation or death

risk of bias not assessable

meta-analysis

Skipper , 2020   NCT04308668 2 weeks ago

hydroxychloroquine 600mg vs. placebo - COVID 19 outpatients some concern in risk of bias

    change in symptom severity over 14 days did not differ between the hydroxychloroquine and placebo groups (difference in symptom severity: relative, 12%; absolute, −0.27 points [95% CI, −0.61 to 0.07 points]; P = 0.117)

  • inconclusive results for: no ongoing symptoms at 14 days; deaths

meta-analysis

RECOVERY , 2020   4 weeks ago

lopinavir/ritonavir vs. control - COVID 19 hospitalized some concern in risk of bias

    the trial Steering Committee concluded that there is no beneficial effect of lopinavir-ritonavir in patients hospitalised with COVID-19 and closed randomisation to that treatment arm

  • inconclusive results for: 28-day mortality

meta-analysis

Arshad (HCQ) , 2020   OBS 4 weeks ago

hydroxychloroquine vs. control - COVID 19 hospitalized critical risk of bias

  • suggested 66 % decrease in mortality but with a very low degree of certainty due to critical risk of bias

meta-analysis

Arshad (HCQ AZ) , 2020   OBS 4 weeks ago

hydroxychloroquine plus macrolides vs. control - COVID 19 hospitalized critical risk of bias

  • suggested 71 % decrease in mortality but with a very low degree of certainty due to critical risk of bias

meta-analysis

GRECCO-19 , 2020   NCT04326790 5 weeks ago

colchicine vs. standard of care - COVID 19 hospitalized some concern in risk of bias

  • suggested 89 % decrease in clinical deterioration

meta-analysis

Follow-us

This project is supported by a grant of the French Ministry of Health (Hospital Clinical Research Program, PHRC-N) and self-funded by Hospices Civils de Lyon, CNRS UMR5558 LBBE University Lyon-1.

   

- About - Our approach - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons